S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:ZYNE

Zynerba Pharmaceuticals Earnings Date, Estimates, & History

$0.96
-0.03 (-3.03%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.91
$1.01
50-Day Range
$0.86
$2.15
52-Week Range
$0.84
$6.07
Volume
290,596 shs
Average Volume
289,377 shs
Market Capitalization
$41.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.18

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(May. 16)
-$0.21 Beat By $0.02
Consensus EPS
(May. 16)
-$0.23
Skip Charts & View Estimated and Actual Earnings Data

Zynerba Pharmaceuticals Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

Zynerba Pharmaceuticals Estimated Revenue and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.22)($0.22)($0.22)
Q2 20221($0.21)($0.21)($0.21)
Q3 20221($0.22)($0.22)($0.22)
Q4 20221($0.23)($0.23)($0.23)
FY 20224($0.88)($0.88)($0.88)
Q1 20231($0.25)($0.25)($0.25)
Q2 20231($0.26)($0.26)($0.26)
Q3 20231($0.27)($0.27)($0.27)
Q4 20231($0.23)($0.23)($0.23)
FY 20234($1.01)($1.01)($1.01)

ZYNE Earnings Information

Zynerba Pharmaceuticals last issued its quarterly earnings data on May 16th, 2022. The reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.02. Zynerba Pharmaceuticals has generated ($0.94) earnings per share over the last year (($0.94) diluted earnings per share). Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.92) to ($0.68) per share. Zynerba Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off prior year's report dates.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueActions
8/8/2022
(Estimated)
        
5/16/20223/31/2022($0.23)($0.21)+$0.02
3/1/2022Q4 2021($0.27)($0.22)+$0.05($0.22)
11/15/20219/30/2021($0.25)($0.26)($0.01)($0.26)
8/9/20216/30/2021($0.22)($0.25)($0.03)($0.25)
5/12/20213/31/2021($0.25)($0.20)+$0.05($0.20)
3/10/202112/31/2020($0.32)($0.33)($0.01)($0.33)
11/9/20209/30/2020($0.43)($0.31)+$0.12($0.31)
8/10/20206/30/2020($0.45)($0.78)($0.33)($0.78)
5/11/20203/31/2020($0.50)($0.53)($0.03)($0.53)
3/10/202012/31/2019($0.50)($0.46)+$0.04($0.46)
11/6/2019Q3($0.5210)($0.44)+$0.0810($0.08)
8/6/2019Q2 2019($0.4950)($0.503473)($0.008473)($0.50)
5/8/20193/31/2019($0.49)($0.47)+$0.02($0.47)
3/11/201912/31/2018($0.65)($0.44)+$0.21($0.44)$0.09 million
11/8/20189/30/2018($0.70)($0.47)+$0.23($0.47)
8/2/2018Q2 2018($0.77)($0.89)($0.12)($0.89)
5/8/2018Q1 2018($0.6770)($0.91)($0.2330)($0.91)
3/12/2018Q4 2017($0.60)($0.60)($0.60)
11/14/2017Q3 2017($0.5850)($0.6340)($0.0490)($0.63)
8/1/2017Q2 2017($0.60)($0.64)($0.04)($0.64)$0.38 million
5/9/2017Q1 2017($0.5460)($0.60)($0.0540)($0.60)$0.07 million
3/27/2017Q4 2016($0.73)($0.71)+$0.02($0.71)
11/14/2016Q3 2016($0.67)($0.67)($0.67)$0.20 million
8/11/2016Q2 2016($0.53)($0.70)($0.17)($0.70)$0.03 million
5/12/2016Q1 2016($0.54)($0.49)+$0.05($0.49)$0.03 million$0.01 million
3/14/2016Q4 2015($0.59)($0.62)($0.03)($0.62)$0.20 million$0.05 million
11/11/2015Q3 2015($0.41)($0.58)($0.17)($0.50)$0.20 million
8/27/2015Q2 2015($0.80)($0.80)($0.80)$0.02 million
(Earnings results data provided by Zacks Investment Research)












Zynerba Pharmaceuticals (NASDAQ:ZYNE) Earnings Frequently Asked Questions

When is Zynerba Pharmaceuticals's earnings date?

Zynerba Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 8th, 2022 based off last year's report dates. Learn more on ZYNE's earnings history.

Did Zynerba Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported ($0.21) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.23) by $0.02. Learn more on analysts' earnings estimate vs. ZYNE's actual earnings.

How much profit does Zynerba Pharmaceuticals generate each year?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) has a recorded net income of -$37.31 million. ZYNE has generated -$0.94 earnings per share over the last four quarters.

What is Zynerba Pharmaceuticals's EPS forecast for next year?

Zynerba Pharmaceuticals's earnings are expected to grow from ($0.92) per share to ($0.68) per share in the next year.

This page was last updated on 5/21/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.